Market Cap 2.23B
Revenue (ttm) 167.13M
Net Income (ttm) -4.03M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 865.02
Profit Margin -2.41%
Debt to Equity Ratio 0.00
Volume 159,400
Avg Vol 117,010
Day's Range N/A - N/A
Shares Out 19.29M
Stochastic %K 66%
Beta 0.83
Analysts Strong Sell
Price Target $144.56

Company Profile

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI, a dual endothelin and angiotensin II receptor antagonist for immunoglobulin A nephropathy; Ohtuvayre for respiratory disease; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pn...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 550 7500
Address:
555 Heritage Drive, Suite 200, Jupiter, United States
WAJeff
WAJeff Jun. 26 at 11:22 PM
$LGND Lost track of this one since the $60S in 2023. Can’t own ‘em all, I guess.
0 · Reply
Estimize
Estimize Jun. 23 at 11:00 PM
Wall St is expecting 1.42 EPS for $LGND Q2 [Reporting 08/11 BMO] http://www.estimize.com/intro/lgnd?chart=historical&metric_name=eps&utm_co
0 · Reply
Doozio
Doozio Jun. 20 at 2:19 PM
The $LGCY of 🐒🍌🧠⏰♾️ will be $LGND ary if $XBI can ever get in $RYTM with da huckleberries in $HRMY
0 · Reply
swingingtech
swingingtech Jun. 9 at 9:03 PM
$LGND https://wallstreetwaves.com/lgnd-surpasses-key-moving-average-with-bullish-momentum/
0 · Reply
Estimize
Estimize Jun. 9 at 1:01 PM
Wall St is expecting 1.42 EPS for $LGND Q2 [Reporting 08/11 BMO] http://www.estimize.com/intro/lgnd?chart=historical&metric_name=eps&utm_co
0 · Reply
SmartInsider
SmartInsider May. 20 at 10:53 AM
Ligand Pharmaceuticals Inc - $LGND US ranked positive on May 14th, 2025 Learn more: https://www.smartinsider.com/stock-of-the-week/lgnd-us-ranked-positive-on-may-14th-2025/
0 · Reply
himsssss
himsssss May. 20 at 1:19 AM
All respective positions can confirmed on their own investor relations pages Brian Lian - Named as the director in correspondence to the $LGND deal with $SEELQ https://seelostherapeutics.com/discovering-seelos-copy-2/ Bankrupt due to their compound from $LGND https://www.fiercebiotech.com/biotech/after-als-trial-misses-mark-seelos-has-filed-bankruptcy https://www.prnewswire.com/news-releases/seelos-therapeutics-announces-notice-of-delisting-from-nasdaq-and-transfer-of-listing-to-over-the-counter-market-302276319.html Greg Zante- CFO Previously worked as CFO for dance pharmaceutical where the books were cooked. Rebranded and then ran off with investors money. https://www.drugdeliverybusiness.com/dance-biopharm-rebrands-to-aerami-therapeutics/ Aerami therapeutics running off with investors money. https://www.bizjournals.com/triangle/news/2024/08/30/aerami-therapeutics-shuts-down-closed-drugs-pharma.html
0 · Reply
King990
King990 May. 19 at 11:11 PM
$VKTX $LGND Another fraud account, this short will get his ASS squeeze hard soon.
1 · Reply
himsssss
himsssss May. 19 at 10:53 PM
Lets talk about confirmation bias. $VKTX CEO and CFO. Both responsible for bankrupting companies and running with the money. Brian brought $LGND to both VKTX and SEELQ. Seelq is now bankrupt due to their decision to use LGND compound as their backbone and failing the trials. Greg Zante led dance pharmaceutical which rebranded to aerami therapeutics. They ran away without a word after a $20M investment. Let's also not forget VK2735 is also just wegovy with a twist.
1 · Reply
CEOBuysDisclosures
CEOBuysDisclosures May. 14 at 2:10 AM
$LGND CEO purchased 9,510 shares at $105.20 for a total of $1,000,456. Davis Todd C now owns 161,234 shares. https://ceo-buys.com
0 · Reply
Latest News on LGND
Ligand Announces 2025 Investor Day in New York City

Jun 11, 2025, 7:00 AM EDT - 15 days ago

Ligand Announces 2025 Investor Day in New York City


Ligand to Ring the Nasdaq Opening Bell on May 19, 2025

May 14, 2025, 7:00 AM EDT - 6 weeks ago

Ligand to Ring the Nasdaq Opening Bell on May 19, 2025


Ligand Reports First Quarter 2025 Financial Results

May 8, 2025, 7:00 AM EDT - 7 weeks ago

Ligand Reports First Quarter 2025 Financial Results


Ligand to Participate in May Investor Conferences

May 1, 2025, 7:00 AM EDT - 2 months ago

Ligand to Participate in May Investor Conferences


Ligand to Participate in March Investor Conferences

Mar 3, 2025, 7:00 AM EST - 4 months ago

Ligand to Participate in March Investor Conferences


Looking Back On Ligand Pharmaceuticals

Feb 3, 2025, 2:59 PM EST - 5 months ago

Looking Back On Ligand Pharmaceuticals


Ligand to Present at Stifel 2024 Healthcare Conference

Nov 14, 2024, 8:00 AM EST - 8 months ago

Ligand to Present at Stifel 2024 Healthcare Conference


Ligand Reports Second Quarter 2024 Financial Results

Aug 6, 2024, 4:01 PM EDT - 11 months ago

Ligand Reports Second Quarter 2024 Financial Results


Ligand Pharmaceuticals: Solid Performer Performing Solidly

Jul 29, 2024, 2:43 PM EDT - 11 months ago

Ligand Pharmaceuticals: Solid Performer Performing Solidly


Ligand to Acquire APEIRON Biologics AG for $100 Million

Jul 8, 2024, 7:00 AM EDT - 1 year ago

Ligand to Acquire APEIRON Biologics AG for $100 Million


Ligand to Participate in Upcoming Investor Conferences

May 23, 2024, 4:59 PM EDT - 1 year ago

Ligand to Participate in Upcoming Investor Conferences


Ligand Reports First Quarter 2024 Financial Results

May 7, 2024, 4:00 PM EDT - 1 year ago

Ligand Reports First Quarter 2024 Financial Results


WAJeff
WAJeff Jun. 26 at 11:22 PM
$LGND Lost track of this one since the $60S in 2023. Can’t own ‘em all, I guess.
0 · Reply
Estimize
Estimize Jun. 23 at 11:00 PM
Wall St is expecting 1.42 EPS for $LGND Q2 [Reporting 08/11 BMO] http://www.estimize.com/intro/lgnd?chart=historical&metric_name=eps&utm_co
0 · Reply
Doozio
Doozio Jun. 20 at 2:19 PM
The $LGCY of 🐒🍌🧠⏰♾️ will be $LGND ary if $XBI can ever get in $RYTM with da huckleberries in $HRMY
0 · Reply
swingingtech
swingingtech Jun. 9 at 9:03 PM
$LGND https://wallstreetwaves.com/lgnd-surpasses-key-moving-average-with-bullish-momentum/
0 · Reply
Estimize
Estimize Jun. 9 at 1:01 PM
Wall St is expecting 1.42 EPS for $LGND Q2 [Reporting 08/11 BMO] http://www.estimize.com/intro/lgnd?chart=historical&metric_name=eps&utm_co
0 · Reply
SmartInsider
SmartInsider May. 20 at 10:53 AM
Ligand Pharmaceuticals Inc - $LGND US ranked positive on May 14th, 2025 Learn more: https://www.smartinsider.com/stock-of-the-week/lgnd-us-ranked-positive-on-may-14th-2025/
0 · Reply
himsssss
himsssss May. 20 at 1:19 AM
All respective positions can confirmed on their own investor relations pages Brian Lian - Named as the director in correspondence to the $LGND deal with $SEELQ https://seelostherapeutics.com/discovering-seelos-copy-2/ Bankrupt due to their compound from $LGND https://www.fiercebiotech.com/biotech/after-als-trial-misses-mark-seelos-has-filed-bankruptcy https://www.prnewswire.com/news-releases/seelos-therapeutics-announces-notice-of-delisting-from-nasdaq-and-transfer-of-listing-to-over-the-counter-market-302276319.html Greg Zante- CFO Previously worked as CFO for dance pharmaceutical where the books were cooked. Rebranded and then ran off with investors money. https://www.drugdeliverybusiness.com/dance-biopharm-rebrands-to-aerami-therapeutics/ Aerami therapeutics running off with investors money. https://www.bizjournals.com/triangle/news/2024/08/30/aerami-therapeutics-shuts-down-closed-drugs-pharma.html
0 · Reply
King990
King990 May. 19 at 11:11 PM
$VKTX $LGND Another fraud account, this short will get his ASS squeeze hard soon.
1 · Reply
himsssss
himsssss May. 19 at 10:53 PM
Lets talk about confirmation bias. $VKTX CEO and CFO. Both responsible for bankrupting companies and running with the money. Brian brought $LGND to both VKTX and SEELQ. Seelq is now bankrupt due to their decision to use LGND compound as their backbone and failing the trials. Greg Zante led dance pharmaceutical which rebranded to aerami therapeutics. They ran away without a word after a $20M investment. Let's also not forget VK2735 is also just wegovy with a twist.
1 · Reply
CEOBuysDisclosures
CEOBuysDisclosures May. 14 at 2:10 AM
$LGND CEO purchased 9,510 shares at $105.20 for a total of $1,000,456. Davis Todd C now owns 161,234 shares. https://ceo-buys.com
0 · Reply
Estimize
Estimize May. 13 at 10:03 AM
Wall St is expecting 1.40 EPS for $LGND Q2 [Reporting 08/11 BMO] http://www.estimize.com/intro/lgnd?chart=historical&metric_name=eps&utm_co
0 · Reply
ZacksSCR
ZacksSCR May. 12 at 4:17 PM
$LGND: 1Q:25 Results https://buff.ly/9AE4A7J
0 · Reply
Estimize
Estimize May. 8 at 2:06 PM
$LGND reported 1.33 EPS and 45.33 revenue for Q1. http://www.estimize.com/intro/lgnd?chart=historical&metric_name=eps&utm_content=LGND&utm_
0 · Reply
Armonica423
Armonica423 May. 6 at 2:21 PM
$LGND CYDY
0 · Reply
Zellchair
Zellchair May. 5 at 4:54 PM
$RPRX $LGND $XOMA I have written a long review of little-known peers to these companies. Under point “8. Closest comparable peers/stocks”, I write a whole paragraph about each company in tickers above, plus 4 more (Swedish and Canadian peers). Maybe someone here would appreciate reading at least that part.
0 · Reply
ZacksSCR
ZacksSCR Apr. 23 at 1:12 PM
$LGND: Pelthos To Become Public Company https://buff.ly/FeAYZq5
0 · Reply
mikesterz7
mikesterz7 Apr. 17 at 3:33 PM
$CHRO $LGND Channel Therapeutics Stock Soars On Announcement Of Subsidiary’s Merger With Ligand Pharma Units Under the agreement, Ligand’s wholly owned subsidiaries, Pelthos Therapeutics Inc. and LNHC, Inc. will combine with CHRO Merger Sub Inc., a wholly-owned subsidiary of Channel.
1 · Reply
SelectiveTrader
SelectiveTrader Apr. 17 at 1:54 PM
$CHRO low float , solid pipeline with upcoming catalysts looking good all time frames on deal with $LGND 2b cap to get approved drug with 3b addressable market. "CHRO), The merger will be supported by $50 million in capital raised from a group of strategic investors led by Murchinson (“Investor Group”). Upon completion of the transaction, the combined company will operate under the name Pelthos Therapeutics Inc. and trade on the NYSE American exchange under the ticker PTHS. .... initially focus on accelerating the commercialization of Pelthos’ ZELSUVMI™ (berdazimer) topical gel, 10.3%, for the treatment of Molluscum contagiosum infections (“molluscum”) in adults and pediatric patients one year of age and older.1 ZELSUVMI was approved by the U.S. Food and Drug Administration (FDA) in 2024 and is the first and only prescription therapy for molluscum infections approved for use at home by patients, parents, and caregivers. https://finance.yahoo.com/news/ligand-subsidiary-pelthos-therapeutics-combine-100000828.html https://channeltherapeutics.com/management-team/
0 · Reply
briefingcom
briefingcom Apr. 17 at 12:35 PM
$LGND: Ligand Pharma subsidiary Pelthos Therapeutics to combine with Channel Therapeutics ($CHRO); expected to close in the summer of 2025 https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20250417060632LGND&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page
0 · Reply
Jwa68
Jwa68 Apr. 17 at 11:48 AM
$CHRO PIPE shares can't even be sold for 6 months and $LGND owns the majority of the new co shares. They can only be considered long term supportive investors. Shouldn't be a lot of supply available.
1 · Reply
DonCorleone77
DonCorleone77 Apr. 17 at 10:33 AM
$LGND $CHRO Ligand subsidiaries, Chromocell Therapeutics to merge Ligand Pharmaceuticals (LGND) and Channel Therapeutics (CHRO) announced the signing of a definitive merger agreement to combine Ligand's wholly owned subsidiaries, Pelthos Therapeutics Inc. and LNHC, Inc. with CHRO Merger Sub Inc., a wholly owned subsidiary of Channel. The merger will be supported by $50M in capital raised from a group of strategic investors led by Murchinson. Upon completion of the transaction, the combined company will operate under the name Pelthos Therapeutics Inc. and trade on the NYSE American exchange under the ticker "PTHS." Under the terms of the merger agreement, Channel will acquire 100% of the issued and outstanding equity interests of Pelthos, and will change its name to Pelthos Therapeutics. In connection with the transaction, Ligand has agreed to invest $18M in the combined company and the Investor Group has agreed to invest $32M for a total of $50M. Upon completion of the transaction, Plesha will become CEO of the combined company and Knuettel will become CFO. The Board of Directors will consist of Plesha, two independent directors, Peter Greenleaf and Matt Pauls, two board members appointed by Ligand, and an additional two independent directors who are reasonably acceptable to Murchinson, both of whom are current Channel board members.The transaction is expected to close in the summer of 2025, subject to customary closing conditions.
1 · Reply